Identification of a viral agent such as HPV as a cause of diseases implies that successful prophylactic or therapeutic intervention against the viral agent should prevent the diseases it causes. A preexisting viral infection can theoretically be targeted by an antiviral or a therapeutic vaccine.
Successful antivirals have been developed for the treatment of some viral infections, including diseases such as HIV and influenza, but not against viruses such as HPV. A therapeutic vaccine against HPV infection would be highly desirable to prevent the cancer-associated complications of HPV infection, which only develop after many years of infection.
However, despite ongoing efforts to develop effective therapeutic vaccines against HPV and other viral infections, none has been shown to be highly effective clinically, probably because the vaccines have not yet adequately mimicked critical aspects of a curative immune response.
On the other hand, prophylactic vaccines have been developed against a variety of human viral pathogens and are often a cost-effective approach to interfere with the diseases caused by these pathogens. To be widely implemented, a prophylactic vaccine generally needs to confer high-level protection for at least several years without boosting and to be particularly safe, as it is given to healthy individuals.
The recognition of HPV as the cause of cervical cancer and other diseases therefore implied that an effective HPV vaccine should be able to interfere with the benign and malignant conditions attributable to HPV infection. However, approved prophylactic vaccines have been directed against infectious agents that cause systemic disease.
What's more, efforts to develop vaccines against sexually transmitted agents such as HPV whose disease results from local infection had not proven successful. It is believed that neutralizing antibodies form the cornerstone of most prophylactic vaccines, and viruses that cause disease only after passing through the circulation are accessible to the neutralizing antibodies present in the blood.
Another limitation was that the presence of oncogenes in HPVs suggested that a subunit vaccine approach would theoretically be preferable to an inactivated vaccine or an attenuated live-virus vaccine, and it was unclear whether a subunit HPV vaccine would have the potential to be effective against the local infections caused by genital HPVs.
Despite these uncertainties, 2 pharmaceutical companies have recently reported a remarkable degree of protection by candidate prophylactic HPV vaccines. The vaccines that both companies are developing are subunit virus-like particle (VLP) vaccines composed of a single viral protein, L1, which is the major structural (capsid) protein of the virus and contains the immunodominant neutralization epitopes of the virus.
The medical community has not had success to develop a treatment to successfully eradicate existing infections without causing extensive skin damage, trauma, or relapse. Importantly, China has now banned such vaccinations as they have found injecting a pathogen into your system does just that, it stays in your system, remaining latent in the joints, only to reappear in later years causing horrendous arthritis and or auto immune disorders.
For warts, cures don't come much better than WartCure. It is established to eradicate and cure warts time after time. This all-natural topical warts cure treatment exhibits a broad spectrum of action against HPV, the virus that causes warts. It kills HPV and provides a curative effect against warts. It is one of the most powerful and effective topical cures for warts on the market.
WartCure provides a safe and effective alternative to this invasive and expensive treatment. This highly effective wart cure contains certified organic anti-viral extracts that have the demonstrated ability to not only kill the wart virus, but to also stimulate CD4 T-cells. These cells are responsible for cleansing virus-infected cells, making our product superior to other cures for warts because it works without any recurrence, discomfort or tissue damage.
The therapeutic action of WartCure is accomplished via its rapid absorption into the skin. For warts, cures must act quickly in skin tissue. The organic essential oils in WartCure are lipophilic (absorb into fatty tissue such as the skin) and have a low molecular weight. This allows them to pass readily into skin tissue and into the DNA of cell membranes where they attack and destroy the HPV virus.
Organic extracts that demonstrate the greatest antiviral effect against HPV in comprehensive scientific trials, while being tolerable to skin tissue, have been blended to create the superior wart cure solution. In the vast majority of cases, WartCure quickly and effectively removes warts without causing tissue damage or scarring. To learn more, please go to http://www.forcesofnatureusa.com.